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Abstract 
Background: The intention of the present study was to study the structural affection of the lung 
following Methotrexate (MTX) overdose. The proposed underlying mechanisms involved in 
lung affection were studied. The possible modulation role of febuxostat over such affection was 
studied.   
Materials and methods: 24 rats were divided into three groups: control, MTX-treated, 
febuxostat-treated. The study was continued for 2 weeks. Lung was processed for histological 
and immunohistochemical {Inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-
2)} studies. Inflammatory markers (TNF-α, IL-1), Western blot evaluation of NF-κB and 
oxidative/antioxidative markers were done.  
Results: MTX-treated group exhibited inflammatory cellular infiltrations, thickened 
interalveolar septa, dilated congested blood vessels, extravasated blood, and apoptosis. The 
collagen fibers content increased 3-fold. MTX induced lung affection through oxidative stress 
(increase MDA /decrease GSH, SOD) and apoptosis. It induced sterile inflammation through 
increase NF-κB (two -fold), IL-1 (three-fold) and TNF-α (three-fold), COX-2 cells (2 ½-fold) 
and iNOS (6-fold).  With the use of febuxostat, the normal lung architecture was observed with a 
pit thickened interalveolar septum and extravasated blood. The collagen fibres content was 
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minimal. Decrement of oxidative stress and sterile inflammation (COX-2 cells and iNOS were 
comparable to the control group. NF-κB, IL-1 and TNF-α became higher by 34, 64% and 100%). 
Conclusions: The overdose of MTX displays inflammatory lung affection with residual fibrosis. 
It induces lung affection through oxidative stress, apoptosis and sterile inflammation. With the 
use of febuxostat, the normal lung architecture was preserved with a little structural affection or 
fibrotic residue. Febuxostat exerts its lung protection through its anti-inflammatory and 
antioxidant features. 
Key words: febuxostat, methotrexate, lung 
 
 
INTRODUCTION 
Methotrexate (MTX) has displayed effectiveness in treating several diseases, including 
rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel 
disease, psoriasis, and small‐ vessel vasculitis [11, 32]. It is commonly used as a treatment for 
some types of cancer, including breast, ovaries, brain, and leukemia [26]. It is used as an 
alternative to surgical management of ectopic pregnancy in selected patients with small, 
unruptured tubal pregnancies [34]. Adding, it is recommended for induction and maintenance of 
remission in Crohn’s disease [13].   
The therapeutic application of MTX is usually limited by its severe toxicity [38]. It is 
involved as a causative agent in lung toxicity [9, 33]. The prevalence of MTX‐ related lung 
disease and MTX‐ related interstitial lung disease (in rheumatoid arthritis) are 7.6% and 11.6% 
respectively [4, 9].  
Several mechanisms have been studied to recognize the mechanism of MTX-induced 
lung damage. One of these mechanisms is oxidative stress [2]. MTX interferes with the 
antioxidant defense enzymes, depletes glutathione content, and causes lipid peroxidation (Arpag 
et al., 2018). Diminution of antioxidant defenses enhances the production of reactive oxygen 
species (ROS) that result in parenchymal lung injury and interstitial, alveolar fibrosis [24]. Other 
possible mechanism of MTX-induced lung damage is inflammatory reaction of MTX. MTX 
increases the levels of IL-1β, and TNF-α, which are indicators of inflammatory response [1]. 
Adding, overdose of MTX can lead to proinflammatory cytokine release [19]. 
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Febuxostat is a selective xanthine oxidase inhibitor that is used to reduce urate levels in 
diseases that involve hyperuricemia such as gout and tumor lysis syndrome [28, 31]. The focus 
on xanthine oxidase inhibitors has increased due to their anti-inflammatory, antioxidant and 
immune-modulatory features which might be beneficial in the treatment of different auto-
inflammatory diseases [27]. Febuxostat showed anti-inflammatory effects in different 
experimental models [15]. It has an antioxidative stress effect and suppressed ROS production in 
the rat model of renal ischemia-reperfusion injury [36].  
The intention of the present study was to study the structural affection of the lung 
following MTX overdose. The proposed underlying mechanisms involved in lung affection were 
studied. The possible modulation role of febuxostat over such affection was studied.  
 
MATERIALS AND METHODS 
Animals 
Twenty-four Sprague-Dawley adult albino rats were used. The sample size was based 
according to resource equation method [10, 16]. The rats were housed in a temperature (22 ± 
2°C), relative humidity (55% ± 5%), and light/dark cycle (12/12-h). The study was conducted in 
Experimental Animal Centre, Cairo University. The experiment was carried out in accordance to 
ARRIVE guidelines (Animal Research: Reporting of In-Vivo Experiments) with the approval of 
the local IACUC Research Ethics Committee and according to ethical standards of National 
Institutes of Health guide for care and use of Laboratory Animals (8th edition, revised in 2011).  
 
Experimental design 
The rats were divided into three groups. Each group consists of 8 rats:  
Control group: 100 mg/kg physiological saline/ intraperitoneally. 
MTX-treated group 
Febuxostat-treated group (concomitant MTX + febuxostat).  
 
Test materials 
MTX was obtained from Pfizer Pharmaceutical Company and Chemical industries 
(Egypt) and given a single dose 20 mg/kg, intraperitoneally [2]. The used dose MTX was a high 
dose to evaluate the role of ROS formation and apoptosis [21].  
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Febuxostat was obtained from Hikma Pharmaceutical Co. (Egypt). It was dissolved in 
0.9% saline and given 15 mg/ kg, oral: 2 drops of Tween 80 [15] for 14 successive days. 
 
General toxicological profile 
The general toxicological data were recorded including food and water consumption, 
health status, body weight (BW) and behavioral measures.  
 
Behavioral measures (Anxiety like behavior) 
Two days before the end of the experiment, the rats were subjected to behavioral 
observation to measure anxiety like behavior using two behavioral tests. The rats were 
accustomed to the presence of the experimenter before the behavioral observation. The tests were 
carried out between 9 AM and 12 PM for two days.  
Light/Dark box. This test based on the innate fear of the rat to bright spaces. It is 
composed of a box divided into equal compartment, bright and dark compartments separated by 
a partition with a door. The rat was placed at the bright compartment and allowed to explore for 
5 min. Frequency of entry into dark & light compartments and the time spent in these 
compartments were measured [7].  
Elevated plus maze [37]. This test is based on the rat`s conflict between exploring novel 
places, and avoiding heights and dangerous places. It is composed of wooden two open and 
enclosed arms connected by central platform. The apparatus elevated 60 cm above the ground. 
The rats were placed in the open arm and allowed to explore for 5 min. Frequency of entry to the 
open and closed arms as well as the time spent in each arm were measured.  
 
Tissue sampling 
The lung was dissected and fixed immediately in 10% formalin saline. To randomize 
selection, the entire lung was cut starting at the superior border, every 10th section (5 µm thick) 
was put aside for staining. 
 
Preparation of tissue extracts 
A portion of lungs was homogenized in 10 volumes (1:10; w/v) of ice-cold 10 mM 
phosphate buffered saline (PBS, pH 7.4) in an Ultra Turrax tissue homogenizer for 30 seconds. 
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Homogenates were centrifuged at 10.000 rpm for 10 min at 4 °C. The supernatant was pipetted 
into clean centrifuge tubes and stored in aliquots (- 80 °C) until analysis [12].  
 
Light microscopic study 
Hematoxylin and eosin stain.  
Masson's trichrome stain [35]  
The paraffin sections were dewaxed, rehydrated then stained in acid fuchsin solution for 
5 min, rinsed in distilled water, placed in phosphomolybdic acid solution for 3 min, washed in 
distilled water, stained with methyl blue solution for 2-5 min, rinsed in distilled water, and 
treated in acetic acid for 2 min. Finally, the sections were dehydrated in absolute alcohol, cleared 
in xylol, and mounted in Canada balsam. The nuclei appeared dark red, the cytoplasm appeared 
pale red and, the collagen fibers appeared blue.  
 
Immunohistochemistry [30]  
Immunohistochemical staining using the streptavidin-biotin-peroxidase technique for 
iNOS, and cyclooxygenase (COX)-2 (markers of inflammation). Briefly, 10 sections/ group were 
deparaffinized, rehydrated, and rinsed in tap water, treated with 3% hydrogen peroxide for 10 
min then, immersed in antigen retrieval solution. Non-specific protein binding was blocked by 
incubating the sections in10% normal goat serum in phosphate buffer solution (PBS). Then, the 
sections were incubated in a humid chamber at 4◦C with primary anti-iNOS antibody (rabbit 
polyclonal antibody,1:100dilution, ab15323, Abcam, Cambridge, Massachusetts, USA), anti-NF-
kB antibody (rabbit polyclonal anti-rat antibody against P65 subunit of NF-kB; 1:20 dilution, 
ab86299, Abcam, Cambridge, Massachusetts, USA) and anti-COX-2 (rabbit polyclonal 
antibody,1:100 dilution, ab15191, Abcam, Cambridge, Massachusetts, USA) overnight. After 
washing in PBS, the corresponding biotinylated secondary antibody was added to lung sections 
for one hour at room temperature. Streptavidin peroxidase was added for 10 min and then 
washed in PBS. Finally, the sections were counterstained by Mayer’s hematoxylin. For negative 
control sections, the primary antibodies were excluded. All the slides were assessed in triplicates 
to confirm the accuracy of the obtained results. 
 
Oxidative/antioxidative markers 
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Lung lipid peroxidation. Malondialdehyde (MDA), a marker for lipid peroxidation, was 
measured by monitoring thiobarbituric reactive substances (TBARS) formation. Briefly, 500 mL 
of lung homogenate was added to 200 mL of phosphate buffered saline (PBS, 10 Mm, pH 7.4) 
and 500 µL of heat trichloroacetic acid-butylated hydroxytoluene (20% TCA, 1% BHT) solution. 
The resultant was mixed and centrifuged at 3000 rpm for 10 min 4°C. To 800 mL of supernatant, 
160 µL of 0.6 M HCL and 640 µL of 1.73% thiobarbituric acid (TBA) were added. This 
suspension was mixed and heated in a boiling water bath for 15 minutes. After cooling, the 
thiobarbituric reactive substances (TBARS) were measured in the supernatant at 530 nm against 
a blank containing all reagents except the tissue homogenate. The concentration of MDA was 
calculated and expressed in Nano-moles per milligram of protein. 
Lung SOD activity. Superoxide dismutase activity (SOD) was determined at room 
temperature (RT) according to the modified Misra and Fridovich’s method [23]. Five microliters 
of 10% lung homogenate was added to 1965 µl of sodium carbonate buffer and to 10 microliters 
of bovine catalase. Twenty microliters of 30 mM epinephrine (dissolved in 0.05% acetic acid) 
was added to the mixture. Superoxide dismutase activity was measured at 480 nm for 5 min on a 
spectrophotometer. The activity was expressed as the amount of the enzyme that inhibits the 
oxidation of epinephrine by 50%, which is equal to 1 U per milligram of protein. 
Lung glutathione (GSH). Glutathione was measured spectrophotometrically in the 
bronchoalveolar lavage fluid (BALF) and lung tissue [29]. GSH was measured by adding the 
standard or sample to 100 µL of a 1:1 mixture of 3 units/mL glutathione reductase with 0.67 
mg/mL 5,5’-Dithiobis 2-  nitro benzoic acid) (DTNB). The reaction was initiated by the addition 
of 20 µL of 0.67 mg/mL NADPH and the increase in absorbance at 412 nm was monitored by 
using a commercial kit (Biodiagnostic, Cairo, Egypt). Values measured in BALF were 
normalized to urea, values in lung tissue were normalized to protein content. For in vitro samples 
both the media and lysate were normalized to the lysate protein. The limit of detection for GSH 
was 0.2 µM. The concentration of the lung GSH was calculated using the standard curve and 
expressed per mg of protein. The level of epithelial lining fluid GSH (ELF GSH) was expressed 
µM. 
 
Western blot assay  
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NF-κB was estimated by the ELISA, according to the constructor’s guide (R&D system 
Inc.). Lung tissue was standardized (1:10) in saline and stockpiled at -80°C. Models were 
preserved with cell lysis buffer, adjusted with PMSF and PIC former to the measures. Samples 
were extra watered down in assay buffer. Later to pipetting 100 µl assay buffer, 100 µl of 
sample/standard were supplemented o the pits.  
The plate was incubated at RT for 1 h. The wells were splashed 5 times with rinse buffer. 
After 1 h incubation, the plate was splashed 5 times with shower buffer and 100 µl of conjugate 
were supplemented to all wells. The plate was vacuum-packed and incubated for 30 min at RT. 
Well matters were let down and rinsed 5 times in buffer. 100 µl of substrate was auxiliary to all 
wells and color endorsed to progress. 30 min later, halt solution was substituted. The plate was 
delivered on an ELISA Plate Reader (OD 450 nm). Rectilinear average curves were created in 
assay buffer to estimate the values of NF-κB.   
 
Image analysis and morphometric measurements 
The area percent of collagen fibers and immune expression of iNOS, and COX-2 were 
done using Leica LAS V3.8 image analyzer computer system (Switzerland). The measurements 
were obtained by an independent blinded observer. The data was obtained in ten non-overlapping 
microscopic fields taken randomly from each slide and were examined within the standard 
measuring frame. 
 
Biochemical assay 
The serum level of the inflammatory markers TNF-α, and IL-1 were assayed by the 
commercially Enzyme-linked immunosorbent assays (ELISA) kits supplied by Biopsies, China 
according to manufacturer instructions. 
 
Protein assay   
The protein concentration in the lung homogenate was measured by Bradford’s method 
using bovine serum albumin as standard [8]. 
 
Statistical analysis 
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Statistical analysis was performed using statistical package for the social sciences (SPSS) 
version 21.0 (IBM Corporation, Somers, NY, USA) statistical software. Data were expressed as 
means ± standard deviation (SD). Statistical evaluation was done using one-way analysis of 
variance (ANOVA) followed by Bonferroni pairwise comparisons. Significance was considered 
when the p-value was less than 0.05. 
The percentage of increase or decrease (difference) of all study parameters were 
calculated with the following formula: Percentage of difference = (Mean difference value 
between two groups)/(Value of the compared group) x100. 
 
RESULTS  
The general toxicological data 
No mortalities were noticed in the studied groups. The food and water intake and health 
status were relatively excellent.  
At the beginning of study, the BW was 150±3.6 g. By the end of study, the BW of MTX-
treated group decreased by 22% compared to the control group. With use of febuxostat, the BW 
became 12 % less than the control group (Table 1).  
 
Behavioral measures (Anxiety like behavior). 
Light/dark box. There was non-significant difference among the different groups 
concerning time spent in the dark or light compartments. A significant increase (130%) in the 
number of entries of the MXT-treated rats into the dark compartment as compared to the control 
rats. Non-significant entry difference was detected in febuxostat-treated group into dark and light 
compartments as compared to the control group (Fig 1).  
Elevated plus maze. As comparted to the other groups, MXT-treated rats entered the 
open arm of the elevated plus maze less frequent and spent less time. They entered more frequent 
to the closed arm of the elevated plus maze and spent more time (Fig 2a, b). 
Febuxostat-treated rats entered more frequent and spent more time in the open arm (Fig 
2c, d). 
 
Structure of lung as revealed by H&E staining  
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The control group presented normal lung morphology. MTX-treated rats exhibited 
inflammatory cellular infiltrations, thickened interalveolar septa (with edema), dilated congested 
blood vessels, extravasated blood, and apoptotic pneumocytes. With the use of febuxostat, 
normal lung architecture was observed with a pit thickened interalveolar septum and 
extravasated blood (Fig 3, 4). 
 
The content of collagen fibres  
The collagen fibres were minimum in the control group. The fibres content increased 
three-fold in MTX-treated group when compared to the control group. Much improvement was 
noticed in febuxostat-treated group as its fibres contents were comparable to the control group 
(Fig 5, Table 2). 
 
Immunohistochemical evaluation 
The COX-2 (cells/mm2) in the control and febuxostat-treated groups were comparable. 
The immunostained COX-2 cells increased in MTX-treated rats by > 2½-fold (275%) compared 
to the control group (Fig 6, Table 2).  
The immunohistochemical reaction of iNOS was poor in both control and febuxostat-
treated groups. With use of MXT, the reaction in MXT-treated group became 6-fold higher than 
the control group (Fig 7, Table 2).  
 
Western blot assay 
NF-κB was two-fold higher than the control group. With use of febuxostat, NF-κB 
became 34% higher than the control group (Fig 8, Table 3). 
 
Inflammatory and oxidative/antioxidative markers evaluation (Table 3): 
IL-1 and TNF-α were three-fold higher in MTX-treated group than the control group. 
Improvement was noticed with use of febuxostat as IL-1 and TNF-α were 64% and 100% higher 
than the control group.  
MDA was two and half-fold higher than the control group. With use of febuxostat, MDA 
became half fold higher than the control group.  
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GSH and SOD decreased by 60% compared to the control group. Both markers in the 
control and febuxostat-treated groups were alike. 
 
DISCUSSION 
Body weight of MTX-treated rats decreased by 22%. The loss of weight in rats’ model of 
MTX is due anorexia, cachexia, intestinal mucositis, impairment of absorption and digestive 
functions, alteration of the gut barrier, and diarrhea [6, 22]. 
MTX-treated rats showed a significant increase in the anxiety like behavior expressed by 
an increase in the number of entries to the dark compartments of the light/dark box and an 
increase in the frequency and duration of closed arm entries in the elevated plus maze. The 
anxiety like behavior is explained in mice by the association of MTX with acute brain toxicity 
and by its ability to induce folate depletion [17]. The anxiety like behavior was reported with 
MTX administration in cancer patients [14]. Much improvement was in febuxostat-treated group 
which attributed to the antidepressant activity of the febuxostat [20]. 
MTX-treated rats exhibited an acute inflammatory process (cellular infiltrations, dilated 
congested blood vessels, thickened interalveolar septa with alveolar edema). Because of severe 
congestion, blood extravasation occurred. Adding, apoptotic pneumocytes were detected. 
The cause of lung affection in MTX-treated group is multifactorial. The major cause of is 
the oxidative stress [21]. Oxidative stress is defined as the shift in the balance between oxidants 
and antioxidants in favor of oxidants [5]. The oxidant marker (MDA) was higher, while the 
antioxidant markers (SOD and GSH) were lower in MTX-treated rats. It is used for measuring 
oxidative damage to lipids resulting from free radicals [3]. Analysis of MDA is sufficient to 
proof and assess the oxidative stress [21]. The elevated MDA is a consequence of the higher 
level of IL-1 and the toxic dose of MTX [21]. 
The sterile inflammation in MTX-treated group was caused by increase NF-κB (two-
fold), IL-1 (three-fold) and TNF-α (three-fold), COX-2 cells (2½ -fold) and iNOS (6-fold). The 
present neutrophils results in ROS formation and tissue damage through release of chemical 
mediators [21]. The higher level of IL-1 and higher dose of MTX increase the secretion of 
proinflammatory cytokines TNF-α [21]. TNF-α is crucially responsible for the pathogenesis of 
oxidative stress and increases ROS [21]. It regulates growth, proliferation, differentiation, and 
viability of activated leukocytes [25]. TNF-α also provokes the cellular release of other 
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cytokines, chemokines, or inflammatory mediators [25]. So, excessive TNF-α secretion leads to 
lung damage by inducing oxidative stress and directly inducing apoptosis. 
 Fibrosis was observed in MTX-treated group (the collagen fibres content increased 3-
fold) as a consequence to oxidative stress and sterile inflammation. 
The third major cause of lung damage in the overdose MTX-treated group is apoptosis. 
Apoptosis is multifactorial. It is induced by higher level of TNF-α which activates the caspase 
enzyme system [21]. Apoptosis is also induced by lipid peroxidation (higher MDA) as MDA is 
the end product of the lipid peroxidation process [5]. Lipid peroxidation results in organ and cell 
damage [21]. The increased observed apoptosis results in excessive release of cytokines and 
enhanced ROS which finally damage the lung tissue [21].   
Another possible cause of lung injury in MXT-treated group is the elevation of iNOS. 
The NO-derived from iNOS appears to induce inflammatory infiltration and oxidative stress. 
These events create a deleterious environment that ultimately leads to cellular damages. It seems 
that disruption of COX-2 activity aggravates the resultant lung damage [18].  
With the use of febuxostat, the normal lung architecture was observed with a pit 
thickened interalveolar septum and extravasated blood. The collagen fibres content was minimal. 
Decrement of oxidative stress and sterile inflammation (COX-2 cells and iNOS were comparable 
to the control group. NF-κB, IL-1 and TNF-α became higher by 34, 64% and 100%).  The 
protective role of febuxostat is due to its anti-inflammatory and antioxidant features [27]. 
Febuxostat showed anti-inflammatory effects in different experimental models [15]. Its 
antioxidative stress effect was proved in in the rat model of renal ischemia-reperfusion injury 
[36].  
In conclusion, the overdose of MTX displays inflammatory lung affection with residual 
fibrosis. It induces lung affection through oxidative stress, apoptosis and sterile inflammation. 
With the use of febuxostat, the normal lung architecture was preserved with a little structural 
affection or fibrotic residue. Febuxostat exerts its lung protection through its anti-inflammatory 
and antioxidant features. 
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Table 1. Body weight in the different groups at the end of study  
 
 
 
 
 
  
The BW at the beginning of the study was 150±3.6 g. 
*P-value significant 
 
 
 
 
 
Group 
BW (g)  
Mean ± 
SD  
Versus group 
Control  185±5  
MTX-treated 145±5 
Control* 
Febuxostat-treated*  
Febuxostat-
treated   
162.6±2.5 
Control* 
MTX-treated* 
15 
 
Table 2. Area % of collagen fibres, iNOS and COX-2; *p-value significant 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Group Area percent 
of collagen 
fibres 
COX-2  
(cells/mm2) 
iNOS 
Control Mean ±SD 1.47±0.54 40 ±5 3.1±0.8 
MTX-
treated 
Mean ±SD 6.0±0.55 150±30 18.0±2.0 
Versus control * * * 
Versus 
febuxostat-
treated  
* * * 
Febuxostat-
treated   
Mean ±SD 2.5±0.38 55±8 5.1±1.7 
Versus control NS NS * 
Versus MTX-
treated 
* * * 
16 
 
Table 3. Inflammatory and oxidative/antioxidative markers; *p-value significant 
 
 
 
 
Figure 1 Anxiety like behavior in the light/dark box test. a: Frequency of entry into the light 
compartment. b: Time spent in the light compartment. c: Frequency of entry into the dark 
compartment. d: Time spent in the dark compartment. * Significant from control group, p=0.006. 
 
Figure 2. Anxiety like behavior in the elevated plus maze teat. a: Open arm entry. b: Open arm 
duration. c: Close arm entry d: Close arm duration. * Significant from control group, p=0.000. 
 
Figure 3. Lung morphology of the different studied groups. Note respiratory bronchiole (rb), 
terminal bronchiole (b), alveolar sac (s), alveoli (v), interalveolar septa (sp) and blood vessels (bv). 
a, b:  Normal lung architecture of the control rats. c, d: inflammatory cellular infiltrations (arrows), 
thickened interalveolar septa, dilated congested blood vessels and extravasated blood of MTX-
treated rats. e, f: Normal lung architecture with a pit thickened interalveolar septum and extravasated 
blood of febuxostat-treated rats. H & E, scale bar, 200 µm (a-f). 
Group NF-κB IL-1 
(pg/mg 
protein) 
TNF-α 
(pg/mg 
protein) 
MDA 
(nmol/mg 
protein) 
GSH 
(µg/mg 
protein) 
SOD 
(nmol/mg 
protein) 
Control Mean ±SD 1.17±0.05 149.0±22.8 123.3±43.1 1.48±0.17 1.65±0.07 8.02±0.39 
MTX-
treated 
Mean ±SD 3.80±0.06 604.0±17.6 506.6±28.4 5.22±0.38 0.66±0.10 3.07±0.24 
Versus control * * * * * * 
Versus 
febuxostat-
treated   
* * * * * * 
Febuxostat-
treated   
Mean ±SD 1.57±0.15 245.0±21.7 256.6±19.0 2.22±0.07 1.69±0.13 7.10±0.72 
Versus control * * * * NS NS 
Versus MTX-
treated 
* * * * * * 
17 
 
 
Figure 4. a:  Normal lung architecture of the control rats. B: inflammatory cellular infiltration, 
extravasated blood (arrowheads), edema (ed), macrophages (thick arrows) and apoptotic 
pneumocytes (thin arrows) of MTX-treated rats. c, Normal lung architecture with a pit congestion 
(arrowheads), macrophages (thick arrows) and apoptotic pneumocytes (thin arrows) of febuxostat-
treated rats. H & E, scale bar, 50 µm (a-c). 
 
Figure 5. a: The collagen fibres (arrows) in the control rats. b:  Increased collagen fibres (arrows) in 
MTX-treated rats. c: Minimal collagen fibres (arrows) in febuxostat-treated rats. Masson’s 
trichrome, scale bar, 200 µm (a-c). 
 
Figure 6. a: Minimal immunostaining of COX-2 (arrows) in the control rats. b, c:  Increased 
staining (arrows) in MTX-treated rats. d: Minimal immunostaining of COX-2 (arrows) in 
febuxostat-treated rats. COX-2 immunostaining, scale bar, 200 µm (a-d). 
 
Figure 7. a: Poor immunohistochemically reaction of iNOS (arrows) in the control rats. b, c: 
increase   immunohistochemically reaction of iNOS (arrows) in MTX-treated rats. d: 
immunohistochemically reaction (arrows) in febuxostat-treated rats. iNOS immunostaining, scale 
bar, 50 µm (a-d). 
 
Figure 8. Western blot assay of NF-κB in the different groups. NF-κB was higher in MXT-treated 
group than the control group. NF-κB was a pit higher in febuxostat-treated rats than the control rats. 
Beta actin was used as internal control to measure the relative quantitation of the expression of the 
target gene.   








